You are here

PAH

Gossamer cuts loose 25% of its staff, ties future to phase 3 trial of tarnished Merck rival

Gossamer cuts loose 25% of its staff, ties future to phase 3 trial of tarnished Merck rival

Fierce Biotech

Flag link:

Merck’s oral cholesterol-lowering drug shows similar efficacy to injectable predecessors as it moves to PhIII: #ACC23

Merck’s oral cholesterol-lowering drug shows similar efficacy to injectable predecessors as it moves to PhIII: #ACC23

Endpoints

clinical trials

Flag link:

Gossamer's PAH Candidate Meets Primary Endpoint, Stumbles on Secondary Measure

Gossamer's PAH Candidate Meets Primary Endpoint, Stumbles on Secondary Measure

BioSpace

Flag link:

Gossamer could put pressure on Merck

Gossamer could put pressure on Merck

EP Vantage

United Therapeutics

Flag link:

Sotatercept- the breakthrough PAH has been waiting for?

Sotatercept- the breakthrough PAH has been waiting for?

Clinical Trials Arena

Flag link:

Is Merck Moving Toward Another Blockbuster Drug Launch?

Is Merck Moving Toward Another Blockbuster Drug Launch?

Motley Fool

Flag link:

Merck nails phase 3 sotatercept win, making good on its $11.5B Acceleron buy

Merck nails phase 3 sotatercept win, making good on its $11.5B Acceleron buy

Fierce Biotech

clinical trials

pulmonary arterial hypertension

Flag link:

Long after first nod for inhaled Tyvaso, United Therapeutics scraps PhIII in PH with COPD

Long after first nod for inhaled Tyvaso, United Therapeutics scraps PhIII in PH with COPD

Endpoints

United Therapeutics

clinical trials

Flag link:

FDA declines to approve United-MannKind's lung disease therapy

FDA declines to approve United-MannKind's lung disease therapy

Yahoo/Reuters

United Therapeutics

Flag link:

Is an Acquisition of Acceleron a Smart Move for Merck?

Is an Acquisition of Acceleron a Smart Move for Merck?

Motley Fool

Flag link:

Merck & Co justifies paying up for Acceleron

Merck & Co justifies paying up for Acceleron

EP Vantage

Flag link:

Merck Strikes with $11 Billion Deal for Acceleron and Phase III PAH Drug

Merck Strikes with $11 Billion Deal for Acceleron and Phase III PAH Drug

BioSpace

Flag link:

Merck emerges as lead bidder in potential Acceleron buyout with deal possible this week — report

Merck emerges as lead bidder in potential Acceleron buyout with deal possible this week — report

Endpoints

Flag link:

MannKind and United Snag Priority Review for Pulmonary Hypertension Drug

MannKind and United Snag Priority Review for Pulmonary Hypertension Drug

BioSpace

United Therapeutics

priority review

Flag link:

Acceleron uncorks more mid-stage data for PAH drug sotatercept as part of the drug's resurrection campaign

Acceleron uncorks more mid-stage data for PAH drug sotatercept as part of the drug's resurrection campaign

Endpoints

Flag link:

J&J aims to create community for PAH patients and their doctors with new Uptravi campaign

J&J aims to create community for PAH patients and their doctors with new Uptravi campaign

Fierce Pharma

pharma marketing

Flag link:

United axes PAH program Trevyent, once bought for cheap in acquisition of a rival, after FDA feedback

United axes PAH program Trevyent, once bought for cheap in acquisition of a rival, after FDA feedback

Endpoints

United Therapeutics

Flag link:

With pipeline setbacks mounting, United snares priority voucher for inhaled formulation of PAH med Tyvaso

With pipeline setbacks mounting, United snares priority voucher for inhaled formulation of PAH med Tyvaso

Endpoints

United Therapeutics

priority review voucher

Flag link:

Bayer’s Adempas meets primary endpoint in phase 4 trial in PAH patients

Bayer’s Adempas meets primary endpoint in phase 4 trial in PAH patients

Pharmaceutical Business Review

clinical trials

Flag link:

Acceleron's PAH drug gets the FDA's red carpet treatment with breakthrough status

Acceleron's PAH drug gets the FDA's red carpet treatment with breakthrough status

Endpoints

breakthrough therapy

Flag link:

Pages